355 related articles for article (PubMed ID: 30669)
21. [Effect of sulfasalazine and its metabolites on prostaglandin and leukotriene liberation from human synovial tissue].
Wittenberg HR; Kleemeyer K; Peskar BM; Peskar BA
Wien Klin Wochenschr; 1991; 103(2):34-9. PubMed ID: 1673814
[TBL] [Abstract][Full Text] [Related]
22. Relationship between rectal mucosal prostaglandin production and water and electrolyte transport in ulcerative colitis.
Rampton DS; Sladen GE
Digestion; 1984; 30(1):13-22. PubMed ID: 6149163
[TBL] [Abstract][Full Text] [Related]
23. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
Casellas F; Papo M; Guarner F; Antolín M; Segura RM; Armengol JR; Malagelada JR
Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):221-6. PubMed ID: 7743303
[TBL] [Abstract][Full Text] [Related]
24. [Local production of eicosanoids in patients with ulcerative colitis].
Lukás K; Lukás M; Jáchymová M
Cas Lek Cesk; 1995 Jan; 134(1):13-7. PubMed ID: 7712517
[TBL] [Abstract][Full Text] [Related]
25. Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and colon in vivo.
Goerg KJ; Wanitschke R; Gabbert H; Breiling J; Franke M; Meyer zum Büschenfelde KH
Digestion; 1987; 37(2):79-87. PubMed ID: 2887473
[TBL] [Abstract][Full Text] [Related]
26. Sulfasalazine and 5-ASA compounds.
Allgayer H
Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
[TBL] [Abstract][Full Text] [Related]
27. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis.
Renzi D; Mantellini P; Calabrò A; Panerai C; Amorosi A; Paladini I; Salvadori G; Garcea MR; Surrenti C
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):62-70. PubMed ID: 9615269
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of salicylazosulfapyridine bioavailability following oral and rectal administration in patients with ulcerative colitis].
Sliwiński Z
Pol Tyg Lek; 1991 Nov 11-25; 46(45-47):879-81. PubMed ID: 1688291
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites.
Collier HO; Francis AA; McDonald-Gibson WJ; Saeed SA
Prostaglandins; 1976 Feb; 11(2):219-25. PubMed ID: 4854
[TBL] [Abstract][Full Text] [Related]
30. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells.
Stevens C; Lipman M; Fabry S; Moscovitch-Lopatin M; Almawi W; Keresztes S; Peppercorn MA; Strom TB
J Pharmacol Exp Ther; 1995 Jan; 272(1):399-406. PubMed ID: 7815356
[TBL] [Abstract][Full Text] [Related]
31. Prostaglandins and ulcerative colitis.
Rampton DS; Sladen GE; Youlten LJ
Gastroenterology; 1980 Jan; 78(1):192-3. PubMed ID: 7350029
[No Abstract] [Full Text] [Related]
32. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
[TBL] [Abstract][Full Text] [Related]
33. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
Rask-Madsen J; Bukhave K; Laursen LS; Lauritsen K
Agents Actions; 1992; Spec No():C37-46. PubMed ID: 1359745
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
Griga T; May B; Pfisterer O; Müller KM; Brasch F
Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
[TBL] [Abstract][Full Text] [Related]
35. Plasma and mucosal prostaglandin E2 as a surrogate marker of ulcerative colitis activity.
Wiercińska-Drapało A; Flisiak R; Prokopowicz D
Rocz Akad Med Bialymst; 2001; 46():60-8. PubMed ID: 11780581
[TBL] [Abstract][Full Text] [Related]
36. Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel.
Rachmilewitz D; Ligumsky M; Haimovitz A; Treves AJ
Gastroenterology; 1982 Apr; 82(4):673-9. PubMed ID: 6949849
[TBL] [Abstract][Full Text] [Related]
37. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis.
Raab Y; Sundberg C; Hällgren R; Knutson L; Gerdin B
Am J Gastroenterol; 1995 Apr; 90(4):614-20. PubMed ID: 7717321
[TBL] [Abstract][Full Text] [Related]
38. Mucosal and plasma prostaglandin E2 in ulcerative colitis.
Wiercinska-Drapalo A; Flisiak R; Prokopowicz D
Hepatogastroenterology; 1999; 46(28):2338-42. PubMed ID: 10521993
[TBL] [Abstract][Full Text] [Related]
39. The ubiquitous prostaglandins and their role in ulcerative colitis.
Kimberg DV
Gastroenterology; 1978 Oct; 75(4):748-50. PubMed ID: 30671
[No Abstract] [Full Text] [Related]
40. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
